Whipplewood Advisors LLC Acquires 592 Shares of Koninklijke Philips N.V. $PHG

Whipplewood Advisors LLC boosted its holdings in Koninklijke Philips N.V. (NYSE:PHG) by 39.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,108 shares of the technology company’s stock after purchasing an additional 592 shares during the period. Whipplewood Advisors LLC’s holdings in Koninklijke Philips were worth $51,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Cerity Partners LLC lifted its stake in Koninklijke Philips by 30.6% in the first quarter. Cerity Partners LLC now owns 80,767 shares of the technology company’s stock worth $2,051,000 after purchasing an additional 18,906 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Koninklijke Philips by 2.5% during the first quarter. Dimensional Fund Advisors LP now owns 4,396,095 shares of the technology company’s stock valued at $111,662,000 after acquiring an additional 106,044 shares during the last quarter. HB Wealth Management LLC bought a new position in shares of Koninklijke Philips during the first quarter valued at about $333,000. Bessemer Group Inc. raised its stake in shares of Koninklijke Philips by 2,935.4% during the first quarter. Bessemer Group Inc. now owns 1,973 shares of the technology company’s stock valued at $51,000 after acquiring an additional 1,908 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Koninklijke Philips by 18.0% during the first quarter. Charles Schwab Investment Management Inc. now owns 72,276 shares of the technology company’s stock valued at $1,836,000 after acquiring an additional 11,018 shares during the last quarter. 13.67% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Wall Street Zen downgraded shares of Koninklijke Philips from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Koninklijke Philips in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy”.

Koninklijke Philips Price Performance

PHG stock opened at $28.90 on Tuesday. Koninklijke Philips N.V. has a 1 year low of $21.48 and a 1 year high of $29.29. The company has a market cap of $27.82 billion, a P/E ratio of 152.08, a PEG ratio of 0.78 and a beta of 0.82. The firm has a 50-day moving average of $27.88 and a 200 day moving average of $25.62. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.26 and a quick ratio of 0.81.

Koninklijke Philips (NYSE:PHG) last released its quarterly earnings results on Tuesday, July 29th. The technology company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.29 by $0.12. Koninklijke Philips had a net margin of 1.00% and a return on equity of 11.95%. The company had revenue of $5.05 billion during the quarter, compared to the consensus estimate of $4.35 billion. On average, sell-side analysts forecast that Koninklijke Philips N.V. will post 1.63 EPS for the current year.

Koninklijke Philips Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.